Volume | 2,895,626 |
|
|||||
News | - | ||||||
Day High | 0.9489 | Low High |
|||||
Day Low | 0.7787 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
HOOKIPA Pharma Inc | HOOK | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.795 | 0.7787 | 0.9489 | 0.8933 | 0.8061 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
6,730 | 2,895,626 | US$ 0.877563 | US$ 2,541,094 | - | 0.41 - 2.05 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:57:46 | formt | 175 | US$ 0.90 | USD |
HOOKIPA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
74.72M | 83.95M | - | 20.13M | -81.58M | -0.97 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
HOOKIPA Pharma News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HOOK Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.75 | 0.9489 | 0.70 | 0.8275849 | 2,871,363 | 0.15 | 20.00% |
1 Month | 0.7119 | 0.9489 | 0.70 | 0.8142146 | 1,203,848 | 0.1881 | 26.42% |
3 Months | 0.645 | 0.9489 | 0.60 | 0.7668578 | 733,238 | 0.255 | 39.53% |
6 Months | 0.4433 | 1.13 | 0.41 | 0.7865038 | 1,606,501 | 0.4567 | 103.02% |
1 Year | 0.9875 | 2.05 | 0.41 | 0.91142 | 1,249,220 | -0.0875 | -8.86% |
3 Years | 12.30 | 20.00 | 0.41 | 1.98 | 1,218,315 | -11.40 | -92.68% |
5 Years | 14.20 | 20.00 | 0.41 | 2.40 | 766,030 | -13.30 | -93.66% |
HOOKIPA Pharma Description
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies. |